Genmab Announces that Janssen has Received Conditional European Marketing Authorization for RYBREVANT® (amivantamab) for Patien
13/12 09:28
Media Release Copenhagen, Denmark, December 13, 2021 The European Commission has granted Janssen- Cilag International NV (Janssen) C onditional M arketing A uthorization for RYBREVANT ® ( amivantamab ) f or the treatment of adult patients with advanced non-small cell lung cancer with activating...